Otsuka Pharmaceutical Acquires Mindset Pharma

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

NewLeaf Brands to Acquire Mindleap Health Inc.

May 20, 2020

Healthcare Services

NewLeaf Brands Inc. signed a non-binding letter of intent to acquire 100% of Mindleap Health Inc. via a share exchange, with consideration of CAD $3.5 million in NewLeaf common shares plus additional cash investments. Mindleap is a digital mental-health and telehealth platform focused on mood, emotion and habit tracking and psychedelic aftercare, and the deal is intended to accelerate Mindleap’s time-to-market and expand NewLeaf’s digital health capabilities.

Beatrice Society Acquires MindSetting

November 15, 2021

Healthcare Services

Toronto-based Beatrice Society has acquired Canadian psychedelic-assisted psychotherapy provider MindSetting to accelerate adoption of the MindSetting TRIP Protocol and expand clinician training and psychedelic-enhanced therapy offerings. The acquisition brings MindSetting’s protocol certification program and clinic experience into Beatrice’s education and consumer/therapy-focused platform to broaden clinical access to ketamine-assisted and other psychedelic therapies across Canada.

Community Psychiatry Acquires MindPath Care Centers

May 11, 2021

Healthcare Services

Community Psychiatry Management, LLC acquired MindPath Care Centers to create a nationally scaled outpatient behavioral health platform, more than doubling locations to 70+ and combining over 350 clinicians. The deal expands access to in-person and telemedicine mental health services, including psychiatry, psychotherapy, TMS and addiction recovery, and positions the combined organization for further growth following Community Psychiatry's recent strategic capital investment.

Cybin Inc. Acquires Small Pharma Inc.

August 28, 2023

Biotechnology

Cybin Inc. has agreed to acquire all issued and outstanding securities of U.K.-based Small Pharma in an all‑share plan of arrangement. The transaction combines Cybin's and Small Pharma's clinical-stage psychedelic therapeutic programs and IP into a single, publicly traded clinical‑stage biopharmaceutical company headquartered in Toronto.

Mindpath Health Acquires Psychiatric Centers at San Diego

March 23, 2022

Healthcare Services

Mindpath Health has acquired Psychiatric Centers at San Diego, adding eight locations and 124 providers to its outpatient behavioral health network. The acquisition expands Mindpath's presence in California—strengthening services including autism therapy and transcranial magnetic stimulation (TMS)—and increases patient access across the greater San Diego area.